AbbVie Inc. (ABBV)
| Market Cap | 356.49B +12.0% |
| Revenue (ttm) | 62.82B +9.5% |
| Net Income | 3.60B -13.3% |
| EPS | 2.03 -13.2% |
| Shares Out | 1.77B |
| PE Ratio | 99.28 |
| Forward PE | 13.53 |
| Dividend | $6.92 (3.43%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 4,915,515 |
| Open | 201.92 |
| Previous Close | 202.71 |
| Day's Range | 200.02 - 202.40 |
| 52-Week Range | 176.57 - 244.81 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 254.82 (+26.43%) |
| Earnings Date | Apr 29, 2026 |
About ABBV
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price target is $254.82, which is an increase of 26.43% from the latest price.
News
AbbVie Transcript: AGM 2026
Record revenues and strong sales growth fueled increased R&D and strategic investments. Shareholders approved director elections, auditor ratification, and executive compensation, but rejected proposals to eliminate supermajority voting and require an independent board chair.
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.
AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW
AbbVie (ABBV) announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week, or DDW, Annual Meeting, May 2-5 in Chicago. AbbVie will present 18
AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®
AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, an...
AbbVie price target raised to $236 from $232 at Evercore ISI
Evercore ISI raised the firm’s price target on AbbVie (ABBV) to $236 from $232 and keeps an Outperform rating on the shares.
AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried
AbbVie delivered a strong earnings beat this week, driven by its immunology portfolio. WSJ's David Wainer explains why Wall Street is still jittery.
Big Pharma M&A set for mega year as patent expiries drive deal urgency
Biotech dealmaking is on pace for a bumper year in 2026, with large drugmakers on an acquisition spree to boost their pipelines ahead of upcoming patent losses.
AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec
MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV), jointly with adMare BioInnovations, today recognized RIME Therapeutics as the recipient of the AbbVie Biotech Innovators Award, a priz...
AbbVie price target raised to $278 from $270 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $278 from $270 and keeps an Overweight rating on the shares. The company reported a solid quarter from the
AbbVie price target raised to $265 from $262 at Canaccord
Canaccord analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $265 from $262 and keeps a Buy rating on the shares. The firm said ABBV delivered upside
Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month
Through its loyalty rewards program Allē, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif.
AbbVie upgraded to Buy at BofA on durable growth
As previously reported, BofA analyst Tim Anderson upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226. The firm believes concerns around competitive erosion
AbbVie upgraded to Buy from Neutral at BofA
BofA upgraded AbbVie (ABBV) to Buy from Neutral with a price target of $234, up from $226.
AbbVie raises FY26 revenue view to about $67.3B from about $67B
FY26 consensus $67.06B.
AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74
Sees Q2 revenue $16.7B, consensus $16.8B.
AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
09:33 EDT AbbVie (ABBV) sees FY26 adjusted gross margin ‘above 84% of sales’
AbbVie says ‘especially pleased’ with immunology and neuroscience results
Says making “meaningful progress” advancing programs. Says fundamentals of business are “strong.” Comments taken from Q1 earnings conference call.
AbbVie Earnings Call Transcript: Q1 2026
First quarter 2026 results surpassed expectations with 12.4% revenue growth and strong performance in immunology and neuroscience. Full-year guidance was raised, pipeline progress continued, and significant investments in manufacturing and R&D were announced.
AbbVie Raises FY Guidance on Immunology, Neuroscience Growth
AbbVie raised its full-year adjusted earnings guidance and reported higher first-quarter revenue, boosted by growth in its immunology and neuroscience portfolios.
AbbVie reports Q1 adjusted EPS $2.65, consensus $2.67
Reports Q1 revenue $15B, consensus $14.72B. “We are off to an excellent start in 2026, with first-quarter results exceeding our expectations. AbbVie’s (ABBV) key growth drivers continue to deliver str...
AbbVie raises FY26 adjusted EPS view to $14.08-$14.28 from $13.96-$14.16
FY26 consensus $14.21. The company’s 2026 adjusted diluted EPS guidance excludes any impact from acquired IPR&D and milestones that may be incurred beyond the first quarter of 2026, as both
AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline
AbbVie on Wednesday reported better-than-expected quarterly revenue and profit, fueled by demand for newer immunology drugs Skyrizi and Rinvoq, as the drugmaker continues to navigate its transition a...
AbbVie Reports First-Quarter 2026 Financial Results
Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 ...
Options Volatility and Implied Earnings Moves Today, April 29, 2026
Today, several major companies are expected to report earnings: Amazon (AMZN), Meta Platforms (META), Ford Motor (F), Alphabet Class A (GOOGL), Microsoft (MSFT), Qualcomm (QCOM), AbbVie (ABBV), Telado...
AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Submission is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional e...